None listed
Conditions
Interventions
Intervention1: cetrorelix acetate injection: GnRH antagonist- cetrorelix acetate 0.25mg subcutaneous will be administerd in study group when follicle size is 16 mm and will be given till follicle rea
Sponsors
Employee state insurance post graduate institute of medicine and researchBASAIDARAPUR
Eligibility
Inclusion criteria
Inclusion criteria: 2. Primary or Secondary infertility 3. BMI â?? 18 â?? 30 kg/ m2 4. Regular menstrual cycles (25-35 days) 5. Normal basal FSH( 6. Patients with unexplained infertility 7. Mild male factor 8. Patency of both or either one of the tubes (HSG/Laprohysteroscopy).
Exclusion criteria
Exclusion criteria: 2. Antral follicle count 4 3. Patients with uterine anomalies. 4. Patients with PCOS (as per Rotterdam criteria) 5. Patients with endometriosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. LH surge and premature lutenisation ( S.LH 20 mIU/ml, S.Prog 1ng/ml)13 2. Pregnancy rate Timepoint: 1. LH surge and premature lutenisation ( S.LH 20 mIU/ml, S.Prog 1ng/ml)13 2. Pregnancy rate | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Number of oocytes 18mm on day of trigger 2. Estradiol levels on the day of trigger 3. Duration of use of GnRH antagonist 4. Amount of gonadotropins used 5. Incidence and severity of OHSS 6. Impact of GnRH antagonists on endometrial thickness. 7. Total duration of therapy Timepoint: one month | — |
Countries
India
Contacts
Public ContactDr Leena Wadhwa
Employee state insurance- post graduate institute if medicine and research,Basaidarapur,Delhi
Outcome results
None listed